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TPS_RAYSTATION and measured planar doses Film_TOMO / 
Film_RAYSTATION was (0.3±0.2)%. 
 
 
 
Conclusion: Raystation fallback planning is an advanced 
feature that allows switching patient plans between 
alternative treatment machines and techniques. This could 
be useful to reduce impact of machine downtime on patient 
treatments. However, this process could introduce potential 
risks as distinct TPS and beam deliveries are involved. The 
results presented here show that a difference between 
calculated HT and mimicked RS fallback plans match the 
measured differences found throughout the end-to-end tests. 
Results based on a 5%/5mm tolerance show that we can 
expect at most 0.3% agreement from the difference between 
original and fallback plans displayed by the RS TPS. Further 
work will involve the study of clinical plans on various tumors 
sites. 
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Purpose or Objective: Monte Carlo (MC) approach is 
considered the gold standard method to perform absorbed 
dose calculations in external radiotherapy[1], because it 
provides the most detailed and complete description of 
radiation fields and particle transport in tissues. Several 
codes are available and recently a new MC Penelope based 
code and graphic platform named PRIMO was developed [2]. 
PRIMO has a user-friendly approach, a suitable and 
competitive characteristic for clinical activity. Nevertheless, 
advanced features such as IMRT are not introduced yet. This 
work is a preliminary study for the PRIMO software as a tool 
for MC based quality control of IMRT treatment. 
 
Material and Methods: The simulated beam parameters of a 
Varian CLINAC 2300 were adjusted based on measurements in 
a water tank for 6 MeV energy and 10x10 cm² field. The 
water tank was divided in 81x81x155 voxels with dimensions 
of 2x2x2 mm³. The Gamma Function (GF) was used for 
agreement assessment and a phase-space was obtained above 
the MLC. A solid water phantom with a PTW OCTAVIUS® 729 
2D ionization chamber array inserted was imaged by a CT 
scan and used in PRIMO. A dynamic IMRT plan was calculated 
by the Eclipse™ TPS and irradiated. The LINAC DynaLog files 
were analysed and the dynamic delivery was divided into 
series of static fields in PRIMO. MATLAB was used to analyse 
the PRIMO output and to create images of dose distributions 
at specific locations. The simulated dose at the ion chamber 
matrix position in the phantom was compared with the 
matrix measurement using the 2D GF through the PTW 
Verisoft program. 
 
Results: The best agreement for the beam parameters of the 
LINAC numerical model was obtained with initial electron 
energy of 5.9±0.2 MeV and beam divergence of 1.5°. The 
gamma function analysis (2%, 2mm) showed that 97% of the 
points was lower than 1, confirming the good agreement with 
the experimental data. For the IMRT plan, the measured and 
simulated dose distributions at the ion chamber matrix (fig 
1A-B) show good agreement, as the gamma points lower than 
1 were 96% (fig 1C). 
 
 
Conclusion: This preliminary study shows that an IMRT plan 
was successfully simulated through PRIMO with acceptable 
concordance with the experimental results. Even though 
further studies on more complex treatments are still 
required, the results confirm PRIMO as a promising tool for 
IMRT simulation in clinical environment. 
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Purpose or Objective: The aim of this paper is to evaluate 
the EPID detector sensitivity and specificity for in vivo 
dosimetry of VMAT treatments to identify dosimetric and 
geometric errors and anatomical variations. 
 
Material and Methods: Measurements were performed by 
using TrueBeam STx accelerator equipped with EPID aSi1000 
(Varian, Palo Alto, CA) and PerFraction (PF) software (Sun 
Nuclear Corporation, Melbourne, FL). PF is a commercial 
EPID-based dosimetry software, which allows performing 
transit dosimetry, to provide an independent daily 
verification of the treatment. Performance of the EPID 
detector and of the PF software on anthropomorphic 
phantom was studied, simulating 17 perturbations of the 
reference VMAT plan. Systematic variations in dose values 
(1%-5% output variation), shifts (2,5-11 mm in anterior 
direction), anatomical variations (adding bolus over 
phantom), and MLC positioning (locked leaf position for 
different arc extensions) were applied. The difference in 
local and global gamma pass rate (%GP) between the no-error 
and error-simulated measurements with 1%/1mm, 2%/2 mm 
and 3%/3 mm tolerances was calculated. The clinical impact 
of these errors was also analyzed through the calculation of 
the difference between the reference DVH and the perturbed 
DVH (%DE). We defined as clinically meaningful a variation 
higher than 3% between calculated and perturbated doses. A 
value of %GP equal to 95% and 90% and %DE equal to 3% were 
used as thresholds to calculate sensitivity and specificity.  
 
Results: Repeatability and reproducibility of no-error 
measurements were excellent with %GP=100% for all gamma 
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methods. 1%/1mm and local normalization is able to detect 
all type of errors (1%/1mm with global normalization is not 
able to detect the systematic shift of 2,5 mm), but it could 
overestimates some errors that have not clinical impact. In 
the table, we reported the results of sensitivity and 
specificity of PF to detect clinically relevant errors.  
 
 
 
Conclusion: EPID device and PF software can be confidently 
used in clinical routine to detect dosimetric, geometrical and 
anatomical discrepancies. The possibility of this in vivo 
evaluation and the potentiality of this new system have a 
very positive impact on improving daily patient QA .  
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Purpose or Objective: The aim of this work is to evaluate 
the perturbed DVHs generated from Tomotherapy dose 
distributions according to the dose discrepancies detected 
with pre-treatment measurements. Through perturbed DVHs 
data, sensitivity and specificity of gamma passing rate (%GP) 
were calculated to evaluate if Gamma Index (GI) metric 
correctly differentiates the high dose error plans from low 
dose error plans. In the literature GI was found to be a poor 
predictor of dosimetric accuracy with planar and volumetric 
dosimeters for IMRT and VMAT techniques, we evaluate if this 
lack of prediction of GI method is valid also for Tomotherapy 
plans. 
 
Material and Methods: 12 patients for prostate cancer (P), 
and 12 for head and neck (HN) cancer, were enrolled in the 
study. All the treatments were delivered using the Helical 
Tomotherapy Hi-ART system (Accuray, Inc., Sunnyvale, CA). 
Pre-treatment QA measurements were performed by using 
the diode array ArcCHECKTM and perturbed DVHs were 
obtained with the 3DVH software (both by Sun Nuclear 
Corporation, Melbourne, FL). Measured and calculated dose 
distributions were compared using the global and local GI 
method with 2%/2 mm, and 3%/3 mm criteria. Low-dose 
thresholds (TH) of 10% and 30% were applied and analyzed. 
Percentage dose differences between DVHs, obtained by TPS 
and by 3DVH were calculated. A %GP equal to 95% and a 
mean absolute DVH 3% dose error were used as thresholds to 
calculate sensitivity and specificity. In order to quantify the 
sensitivity and specificity of GI method, we calculated the 
number of false negative (high Tomotherapy QA passing rates 
indicate large errors in anatomy dose metrics), true positive 
(low Tomotherapy QA passing rates do imply large errors in 
anatomy dose metrics), true negative (high Tomotherapy QA 
passing rates did imply small errors in anatomy dose metrics) 
and false positive (low Tomotherapy QA passing rates did 
imply small errors in anatomy dose metrics). 
 
Results: We found the higher sensitivity (0.55) for global 
normalization with 3%/3mm and TH=30% and the higher 
specificity (0.67) with 3%/3mm for global normalization, both 
for TH 10% and 30%. Instead we obtained the poorer 
sensitivity (0) with 2%/2mm, local normalization, and TH=10% 
because the threshold of 95% is too high for 2%/2mm and 
local normalization. We observed the poorer specificity 
(0.39) for 3%/3mm, local normalization, both for TH=10% and 
30%. For global normalization, 3%/3mm sensitivity and 
specificity were always higher than those of 2%/2mm 
criterion. 
 
Conclusion: The low sensitivity and specificity values of GI 
method, for all the applied criteria, show that the gamma 
index metric have disputable predictive power for per-
patient Tomotherapy QA. 
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Purpose or Objective: The gamma index (γ) is a common 
method for comparing measured and predicted dose 
distributions. The percentage of points passing with γ<1 (Γ) is 
the most frequently reported analysis metric. However, the 
use of Γ has been reported to have weak correlation against 
clinically relevant metrics and the result also varies 
depending on the Quality Assurance (QA) system 
configuration and software used. Other metrics could be 
extracted from the γ map but have not been rigorously 
evaluated in the literature to address appropriate acceptance 
values. This study has developed a methodology to evaluate 
the suitability of the mean, median, maximum, or near-
maximum γ metrics (γmean, γmedian, γmax, γ1%) and their 
acceptance criteria. 
 
Material and Methods: Investigations were performed using 
simulated data with deliberate changes created in a virtual 
phantom test. The changes included: dose deviations of -5% 
to 5% in 1% steps; and MLC offsets of 1–5mm in 1mm steps. An 
in-house Matlab-based software was used to perform γ 
analysis to extract different metrics. The primary PTV mean 
(PTVmean) and organ at risk maximum (OARmax) dose 
deviations were extracted from the changed plans. The γ 
metrics were correlated against PTVmean and OARmax for 
global γ passing criteria of 3%/2mm (20% threshold relative to 
a point in high dose low gradient). Acceptance criteria 
needed to predict a dose deviation >±3%, for 3%/2mm, were 
assessed using Receiver Operator Characteristic (ROC) 
analysis and assuming 100% sensitivity. The area under the 
ROC curve (AUC) was assessed for each γ metric to assess 
statistical reliability. Since the γ calculation can give varying 
results between different QA systems, the robustness of the 
proposed methodology was tested by varying γ passing 
criteria as well calculating in 2D planes and 3D volumes. 
 
Results: The γmean, γmedian and γ1% metrics had the 
strongest Pearson correlation coefficient (ρ) against the 
PTVmean (ρ>0.95, p<0.01); (Fig. 1). The Γ had a weaker 
correlation of ρ=-0.76. These metrics had ROC AUC>0.9 
(p<0.01) showing statistically strong accuracy for predicting a 
PTVmean deviation >±3% for 3%/2mm. Optimal acceptance 
criteria for achieving 100% sensitivity are shown in Table 1. 
The γmax had the best correlation against OARmax (ρ> 0.8, 
p<0.01) and the AUC was >0.9 and showed that points with 
γ>1.1 may be associated with a >3% increase in the OARmax. 
Correlations between different γ passing criteria were 
statistically strong at >0.95 (p<0.01) as were correlations 
between 2D & 3D γ calculations, indicating the robustness of 
the methodology to the variability in γ calculation that could 
be caused by QA system configuration and software 
implementation. 
 
